Drug Manufacturers Should Expect No Relief From China’s Rising API Prices
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - API prices in China have increased since the end of last year, and prices are expected to continue to rise with the addition of new costs associated with stronger environmental protection standards, according to analysts